SCHEMBL702364

SCHEMBL702364

COC(=O)c1ccc(-c2ccc(C(C)=O)o2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.51
TP53 P04637 1/20 0.51
RXFP1 Q9HBX9 1/20 0.51
ALDH1A1 P00352 6/20 0.50
KDM4E B2RXH2 4/20 0.50
NPC1 O15118 3/20 0.50
RAB9A P51151 3/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
LOXL2 Q9Y4K0 1/20 0.50
APAF1 O14727 1/20 0.50
TDP2 O95551 1/20 0.50
NSD2 O96028 1/20 0.50
POLB P06746 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
SIRT2 Q8IXJ6 1/20 0.50
PHGDH O43175 1/20 0.49
TNKS O95271 1/20 0.49
NQO2 P16083 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL700768 0.83 ALDH1A1 (0.56) MAPTTP53RXFP1ALDH1A1KDM4E
SCHEMBL699963 0.81 ALDH1A1 (0.54) MAPTTP53ALDH1A1KDM4ENPC1
SCHEMBL23091176 0.81 MAPT (0.62) MAPTTP53ALDH1A1KDM4ENPC1
SCHEMBL5655892 0.81 GSK3B (0.64) MAPTALDH1A1KDM4ENPC1RAB9A
SCHEMBL16346518 0.80 HPGD (0.53) ALDH1A1KDM4EMEN1KMT2APOLB
SCHEMBL12140121 0.80 ALDH1A1 (0.54) MAPTALDH1A1KDM4ENPC1RAB9A
SCHEMBL22545602 0.78 CA12 (0.48) MAPTTP53RXFP1ALDH1A1KDM4E
SCHEMBL4399339 0.78 KDM4E (0.72) MAPTTP53ALDH1A1KDM4ENPC1
SCHEMBL11725201 0.78 MAPT (0.56) MAPTTP53RXFP1ALDH1A1KDM4E
SCHEMBL11813532 0.77 ALDH1A1 (0.50) MAPTTP53RXFP1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120190669-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. (US) 2012-07-26 US disclosed
US-20120190669-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. (US) 2012-07-26 US disclosed
US-20120190669-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. (US) 2012-07-26 US disclosed
US-8124649-B2 Oxindole compounds CYLENE PHARMACEUTICALS, INC. (US) 2012-02-28 US disclosed
US-8124649-B2 Oxindole compounds CYLENE PHARMACEUTICALS, INC. (US) 2012-02-28 US disclosed
US-8124649-B2 Oxindole compounds CYLENE PHARMACEUTICALS, INC. (US) 2012-02-28 US disclosed
CN-102137866-A Oxindole compounds CYLENE PHARMACEUTICALS INC 2011-07-27 CN disclosed
EP-2307421-A1 OXINDOLE COMPOUNDS Cylene Pharmaceuticals, Inc. (US) 2011-04-13 EP disclosed
US-20100041635-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. 2010-02-18 US disclosed
US-20100041635-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. 2010-02-18 US disclosed
US-20100041635-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. 2010-02-18 US disclosed
WO-2010002933-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. (US) 2010-01-07 WO disclosed
WO-2010002933-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041635-A1 OXINDOLE COMPOUNDS FLT3, PIM1, PIM2 MAPT 2199/4885TP53 249/4885RXFP1 1938/4885
US-20120190669-A1 OXINDOLE COMPOUNDS FLT3, PIM1, PIM2 MAPT 2199/4885TP53 249/4885RXFP1 1938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.